Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

10/11/2015 Natura Bissé in the Barcelona Synchrotron Park 05/11/2015 Two Research Centers Awarded at the UAB University 28/10/2015 How ideas grow, the new Barcelona Synchrotron Park video 20/10/2015 Welcome to Barcelona 08/10/2015 Good News for Two PRUAB Spin-Offs 30/09/2015 BSC-CNS Director, Prof. Valero, Recipient of the Seymour Cray Computer Engineering Award
29 30 31 32 33 34 35 36 37 38 39